NASDAQ:PRFX PainReform (PRFX) Stock Price, News & Analysis → Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks (From The Oxford Club) (Ad) Free PRFX Stock Alerts $0.52 -0.03 (-5.45%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.48▼$0.5750-Day Range$0.52▼$1.7052-Week Range$0.48▼$26.41Volume337,652 shsAverage Volume228,013 shsMarket Capitalization$1.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get PainReform alerts: Email Address Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About PainReform Stock (NASDAQ:PRFX)PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Read More PRFX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRFX Stock News HeadlinesMay 31, 2024 | globenewswire.comPainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 16, 2024 | finanznachrichten.dePainReform Ltd: PainReform Provides Business Update for the First Quarter of 2024May 15, 2024 | msn.comPRFX Stock Earnings: PainReform Misses EPS for Q1 2024May 15, 2024 | globenewswire.comPainReform Provides Business Update for the First Quarter of 2024May 8, 2024 | globenewswire.comPainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comApril 18, 2024 | globenewswire.comPainReform Announces Closing of $4 Million Public OfferingApril 16, 2024 | finance.yahoo.comPainReform Announces Pricing of $4 Million Public OfferingApril 9, 2024 | msn.comEXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing ConditionsApril 9, 2024 | finance.yahoo.comPainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | globenewswire.comPainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 4, 2024 | finance.yahoo.comUK watchdog says Theramex-Viatris deal raises competition concernsApril 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management MarketApril 2, 2024 | finance.yahoo.comEXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain DrugApril 2, 2024 | globenewswire.comPainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyMarch 7, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid CrisisMarch 1, 2024 | globenewswire.comPainReform Provides Year-End Business UpdateJanuary 22, 2024 | finance.yahoo.comPainReform to Present at the Microcap Conference in Atlantic CityJanuary 12, 2024 | msn.comPainReform files to sell 968,545 ordinary shares for holdersJanuary 5, 2024 | markets.businessinsider.comBuy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market AdvantageJanuary 3, 2024 | finance.yahoo.comPainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain ReliefDecember 26, 2023 | finance.yahoo.comPainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross ProceedsDecember 19, 2023 | benzinga.comPainReform Stock (NASDAQ:PRFX) Dividends: History, Yield and DatesNovember 19, 2023 | finanznachrichten.dePainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023November 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)November 15, 2023 | finance.yahoo.comPainReform Provides Business Update for the Third Quarter of 2023See More Headlines Receive PRFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/15/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRFX CUSIPN/A CIK1801834 Webwww.painreform.com Phone972-3717-7051FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.61 Quick Ratio1.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.65 per share Price / Book0.11Miscellaneous Outstanding Shares2,030,000Free Float1,329,000Market Cap$1.06 million OptionableNot Optionable Beta0.67 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Ehud Geller Ph.D.Executive ChairmanMr. Ilan Hadar M.B.A. (Age 55)CEO & CFO Comp: $404kDr. Sigal Aviel (Age 60)Chief Operating Officer Comp: $345kProf. Eli Hazum Ph.D.CTO & DirectorMs. Rita Keynan (Age 55)Vice President of Pharmaceutical Operations Comp: $302kDr. Stephen A. Cooper D.M.D Ph.D.Executive Vice President of DevelopmentMore ExecutivesKey CompetitorsSeelos TherapeuticsNASDAQ:SEELProcessa PharmaceuticalsNASDAQ:PCSALipella PharmaceuticalsNASDAQ:LIPOEvoke PharmaNASDAQ:EVOKYumanity TherapeuticsNASDAQ:YMTXView All Competitors PRFX Stock Analysis - Frequently Asked Questions How have PRFX shares performed in 2024? PainReform's stock was trading at $2.75 at the beginning of 2024. Since then, PRFX stock has decreased by 81.1% and is now trading at $0.52. View the best growth stocks for 2024 here. Are investors shorting PainReform? PainReform saw a decline in short interest in May. As of May 31st, there was short interest totaling 15,800 shares, a decline of 47.2% from the May 15th total of 29,900 shares. Based on an average daily volume of 146,300 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.8% of the company's shares are short sold. View PainReform's Short Interest. When is PainReform's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our PRFX earnings forecast. How were PainReform's earnings last quarter? PainReform Ltd. (NASDAQ:PRFX) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($2.72) earnings per share for the quarter. When did PainReform's stock split? PainReform's stock reverse split on the morning of Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of PainReform own? Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU). When did PainReform IPO? PainReform (PRFX) raised $20 million in an initial public offering on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar served as the underwriters for the IPO. How do I buy shares of PainReform? Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRFX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.